Strategies for early detection of resectable pancreatic cancer

World Journal of Gastroenterology

Volumn 20, Issue 32, 2014, Pages 11230-11240

  Okano, Keiichi ^a   Suzuki, Yasuyuki ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Biomarker; Early detection; High risk group; Imaging; Pancreatic cancer; Resectable; Screening

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; EPIGENETICS; GENE TARGETING; GENETIC MARKER; HIGH RISK POPULATION; HUMAN; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRECANCER; PREDICTIVE VALUE; PROTEOMICS; RESECTABLE PANCREATIC CANCER; REVIEW; BLOOD; DIAGNOSTIC IMAGING; GENETIC SCREENING; GENETICS; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PATHOLOGY; PATIENT SELECTION; PROCEDURES; RISK ASSESSMENT; RISK FACTOR;

DIAGNOSTIC IMAGING; EARLY DETECTION OF CANCER; GENETIC TESTING; HUMANS; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84909592624     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i32.11230     Document Type: Review

References (117)

1. Egawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T, Maguchi H, Yanagisawa A, Tanaka M. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas 2012; 41: 985-992 [PMID: 22750974 DOI: 10.1097/MPA.0b013e318258055c]
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300 [PMID: 20610543 DOI: 10.3322/caac.20073]
3. Páez D, Labonte MJ, Lenz HJ. Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol Clin North Am 2012; 41: 189-209 [PMID: 22341258 DOI: 10.1016/j.gtc.2011.12.004]
4. Howlader NNA, Krapcho M. SEER Cancer Statistics Review 1975-2009. USA: National Cancer institute, 2012
5. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL, Kern SE, Yeo CJ, Hruban RH, Goggins M. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001; 7: 4115-4121 [PMID: 11751510]
6. Yeo CJ, Cameron JL. Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg 1998; 383: 129-133 [PMID: 9641885]
7. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721-31; discussion 731-3 [PMID: 7794076]
8. Ariyama J, Suyama M, Ogawa K, Ikari T. [Screening of pancreatic neoplasms and the diagnostic rate of small pancreatic neoplasms]. Nihon Rinsho 1986; 44: 1729-1734 [PMID: 3537369]
9. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117 [PMID: 20981102 DOI: 10.1038/nature09515]
10. NCCN pancreatic adenocarcinoma guidelines. Version 1. 2014. Available from: URL: http://www.nccn.org/professionals/physician-gls/pdf/pancreaticpdf
11. Lynch SM, Vrieling A, Lubin JH, Kraft P, Mendelsohn JB, Hartge P, Canzian F, Steplowski E, Arslan AA, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Petersen G, Zheng W, Albanes D, Amundadottir L, Bingham SA, Boffetta P, Boutron-Ruault MC, Chanock SJ, Clipp S, Hoover RN, Jacobs K, Johnson KC, Kooperberg C, Luo J, Messina C, Palli D, Patel AV, Riboli E, Shu XO, Rodriguez Suarez L, Thomas G, Tjønneland A, Tobias GS, Tong E, Trichopoulos D, Virtamo J, Ye W, Yu K, Zeleniuch-Jacquette A, Bueno-de-Mesquita HB, Stolzenberg-Solomon RZ. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009; 170: 403-413 [PMID: 19561064 DOI: 10.1093/aje/kwp134]
12. Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas 2011; 40: 339-351 [PMID: 21412116 DOI: 10.1097/MPA.0b013e318209e05d]
13. Tanno S, Nakano Y, Koizumi K, Sugiyama Y, Nakamura K, Sasajima J, Nishikawa T, Mizukami Y, Yanagawa N, Fujii T, Okumura T, Obara T, Kohgo Y. Pancreatic ductal adenocarcinomas in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms. Pancreas 2010; 39: 36-40 [PMID: 19745777 DOI: 10.1097/MPA.0b013e3181b91cd0]
14. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H, Li Z. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011; 47: 1928-1937 [PMID: 21458985 DOI: 10.1016/j.ejca.2011.03.003]
15. Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Griffin C, Cameron JL, Yeo CJ, Kern S, Hruban RH. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64: 2634-2638 [PMID: 15059921 DOI: 10.1158/0008-5472.can-03-3823]
16. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-347 [PMID: 23135763 DOI: 10.1136/gutjnl-2012-303108]
17. McKay CJ, Glen P, McMillan DC. Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol 2008; 22: 65-73 [PMID: 18206813 DOI: 10.1016/j.bpg.2007.11.007]
18. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 2010; 24: 349-358 [PMID: 20510834 DOI: 10.1016/j.bpg.2010.02.007]
19. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK, Perrault J, Whitcomb DC. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997; 89: 442-446 [PMID: 9091646 DOI: 10.1093/jnci/89.6.442]
20. Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog 2012; 51: 14-24 [PMID: 22162228 DOI: 10.1002/mc.20855]
21. van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010; 105: 1258-164; author reply 1265 [PMID: 20051941 DOI: 10.1038/ajg.2009.725]
22. Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006; 4: 408-415 [PMID: 16616343 DOI: 10.1016/j.cgh.2005.11.005]
23. Matsubayashi H, Fukushima N, Sato N, Brune K, Canto M, Yeo CJ, Hruban RH, Kern SE, Goggins M. Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer. Cancer Biol Ther 2003; 2: 652-655 [PMID: 14688470 DOI: 10.4161/cbt.2.6.530]
24. Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, Bandipalliam P, Stoffel EM, Gruber SB, Syngal S. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009; 302: 1790-1795 [PMID: 19861671 DOI: 10.1001/jama.2009.1529]
25. Geary J, Sasieni P, Houlston R, Izatt L, Eeles R, Payne SJ, Fisher S, Hodgson SV. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 2008; 7: 163-172 [PMID: 17939062 DOI: 10.1007/s10689-007-9164-6]
26. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, van Houwelingen JC, van't Veer LJ, Rookus MA, van Leeuwen FE. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005; 42: 711-719 [PMID: 16141007 DOI: 10.1136/jmg.2004.028829]
27. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 1358-1365 [PMID: 12237281 DOI: 10.1093/jnci/94.18.1358]
28. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, Ali SZ, Jagannath S, Petersen GM, Fishman EK, Piantadosi S, Giardiello FM, Hruban RH. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2: 606-621 [PMID: 15224285]
29. Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, Fishman EK, Brune K, Axilbund J, Griffin C, Ali S, Richman J, Jagannath S, Kantsevoy SV, Kalloo AN. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4: 766-81; quiz 665 [PMID: 16682259 DOI: 10.1016/j.cgh.2006.02.005]
30. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009; 10: 88-95 [PMID: 19111249 DOI: 10.1016/S1470-2045(08)70337-1]
31. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129: 504-511 [PMID: 16083707 DOI: 10.1053/j.gastro.2005.05.007]
32. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993; 159: 101-107 [PMID: 8098623]
33. Cersosimo E, Pisters PW, Pesola G, McDermott K, Bajorunas D, Brennan MF. Insulin secretion and action in patients with pancreatic cancer. Cancer 1991; 67: 486-493 [PMID: 1985741]
34. Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology 2001; 121: 640-645 [PMID: 11522748 DOI: 10.1053/gast.2001.27210]
35. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80: 1047-1050 [PMID: 8402064]
36. Tsuchiya R, Noda T, Harada N, Miyamoto T, Tomioka T, Yamamoto K, Yamaguchi T, Izawa K, Tsunoda T, Yoshino R. Collective review of small carcinomas of the pancreas. Ann Surg 1986; 203: 77-81 [PMID: 3942423]
37. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134: 981-987 [PMID: 18395079 DOI: 10.1053/j.gastro.2008.01.039]
38. Ishikawa O, Ohigashi H, Imaoka S, Nakaizumi A, Uehara H, Kitamura T, Kuroda C. Minute carcinoma of the pancreas measuring 1 cm or less in diameter - collective review of Japanese case reports. Hepatogastroenterology 1999; 46: 8-15 [PMID: 10228758]
39. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, Biankin SA, Compton C, Fukushima N, Furukawa T, Goggins M, Kato Y, Klöppel G, Longnecker DS, Lüttges J, Maitra A, Offerhaus GJ, Shimizu M, Yonezawa S. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004; 28: 977-987 [PMID: 15252303]
40. Tollefson MK, Libsch KD, Sarr MG, Chari ST, DiMagno EP, Urrutia R, Smyrk TC. Intraductal papillary mucinous neoplasm: did it exist prior to 1980? Pancreas 2003; 26: e55-e58 [PMID: 12657965]
41. Sohn TA, Yeo CJ, Cameron JL, Iacobuzio-Donahue CA, Hruban RH, Lillemoe KD. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg 2001; 234: 313-21; discussion 321-2 [PMID: 11524584]
42. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Klöppel G, Longnecker DS, Lüttges J, Offerhaus GJ. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25: 579-586 [PMID: 11342768]
43. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, Decaprio JA, Srivastava S, Hanash SM, Hruban RH, Pandey A. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009; 6: e1000046 [PMID: 19360088 DOI: 10.1371/journal.pmed.1000046]
44. Homma T, Tsuchiya R. The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan, using CA19-9 and elastase-1 or ultrasonography. Int J Pancreatol 1991; 9: 119-124 [PMID: 1744437]
45. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110: 704-709 [PMID: 2930108]
46. Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009; 198: 333-339 [PMID: 19375064 DOI: 10.1016/j.amjsurg.2008.12.031]
47. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988; 6: 462-468 [PMID: 3162513]
48. Maithel SK, Maloney S, Winston C, Gönen M, D'Angelica MI, Dematteo RP, Jarnagin WR, Brennan MF, Allen PJ. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 2008; 15: 3512-3520 [PMID: 18781364 DOI: 10.1245/s10434-008-0134-5]
49. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-971 [PMID: 94699]
50. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006; 24: 252-258 [PMID: 16344318 DOI: 10.1200/JCO.2005.02.8282]
51. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, Vogelstein B, Goggins M. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004; 10: 2386-2392 [PMID: 15073115 DOI: 10.1158/1078-0432.ccr-03-0165]
52. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 1997; 94: 11514-11519 [PMID: 9326641]
53. Buckhaults P, Rago C, St Croix B, Romans KE, Saha S, Zhang L, Vogelstein B, Kinzler KW. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 2001; 61: 6996-7001 [PMID: 11585723]
54. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001; 61: 5974-5978 [PMID: 11507037]
55. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 2003; 63: 4648-4655 [PMID: 12907645]
56. Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, Diamandis EP, Hampton GM, Russell PJ, Giles GG, Breit SN. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 2006; 12: 89-96 [PMID: 16397029 DOI: 10.1158/1078-0432.CCR-05-1331]
57. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006; 12: 442-446 [PMID: 16428484 DOI: 10.1158/1078-0432.CCR-05-0564]
58. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999; 131: 247-255 [PMID: 10454945]
59. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W, Campbell F, Brentnall TA, Costello E, Neoptolemos J, Lemoine NR. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 2005; 129: 1454-1463 [PMID: 16285947 DOI: 10.1053/j.gastro.2005.08.012]
60. Chen R, Yi EC, Donohoe S, Pan S, Eng J, Cooke K, Crispin DA, Lane Z, Goodlett DR, Bronner MP, Aebersold R, Brentnall TA. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 2005; 129: 1187-1197 [PMID: 16230073 DOI: 10.1053/j.gastro.2005.08.001]
61. Grønborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, Molina H, Jensen ON, Hruban RH, Goggins MG, Maitra A, Pandey A. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 2006; 5: 157-171 [PMID: 16215274 DOI: 10.1074/mcp.M500178-MCP200]
62. Yu KH, Rustgi AK, Blair IA. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 2005; 4: 1742-1751 [PMID: 16212428]
63. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10: 860-868 [PMID: 14871961 DOI: 10.1158/1078-0432.CCR-1167-3]
64. Bhattacharyya S, Siegel ER, Petersen GM, Chari ST, Suva LJ, Haun RS. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 2004; 6: 674-686 [PMID: 15548376 DOI: 10.1593/neo.04262]
65. Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ, Abbruzzese JL, Kobayashi R. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 2005; 11: 1110-1118 [PMID: 15709178]
66. Lu Z, Hu L, Evers S, Chen J, Shen Y. Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics 2004; 4: 3975-3988 [PMID: 15526344 DOI: 10.1002/pmic.200300863]
67. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004; 64: 9018-9026 [PMID: 15604267 DOI: 10.1158/0008-5472.CAN-04-3262]
68. Pan S, Chen R, Brand RE, Hawley S, Tamura Y, Gafken PR, Milless BP, Goodlett DR, Rush J, Brentnall TA. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J Proteome Res 2012; 11: 1937-1948 [PMID: 22316387 DOI: 10.1021/pr201117w]
69. Berger DH, Chang H, Wood M, Huang L, Heath CW, Lehman T, Ruggeri BA. Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status. Cancer 1999; 85: 326-332 [PMID: 10023699]
70. Tada M, Komatsu Y, Kawabe T, Sasahira N, Isayama H, Toda N, Shiratori Y, Omata M. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 2002; 97: 2263-2270 [PMID: 12358243 DOI: 10.1111/j.1572-0241.2002.05980.x]
71. Yamada T, Nakamori S, Ohzato H, Oshima S, Aoki T, Higaki N, Sugimoto K, Akagi K, Fujiwara Y, Nishisho I, Sakon M, Gotoh M, Monden M. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 1998; 4: 1527-1532 [PMID: 9626473]
72. Mulcahy HE, Lyautey J, Lederrey C, qi Chen X, Anker P, Alstead EM, Ballinger A, Farthing MJ, Stroun M. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998; 4: 271-275 [PMID: 9516910]
73. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32 [PMID: 7726912 DOI: 10.1038/ng0994-27]
74. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53 [PMID: 1905840 DOI: 10.1126/science.1905840]
75. Yan L, McFaul C, Howes N, Leslie J, Lancaster G, Wong T, Threadgold J, Evans J, Gilmore I, Smart H, Lombard M, Neoptolemos J, Greenhalf W. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005; 128: 2124-2130 [PMID: 15940643 DOI: 10.1053/j.gastro.2005.03.006]
76. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, Goggins M. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60: 1835-1839 [PMID: 10766168]
77. Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg 2006; 13: 286-295 [PMID: 16858539 DOI: 10.1007/s00534-005-1057-1]
78. Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, Wilentz RE, Yeo CJ, Hruban RH, Goggins M. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 2002; 160: 1573-1581 [PMID: 12000709 DOI: 10.1016/S0002-9440(10)61104-2]
79. Sato N, Fukushima N, Chang R, Matsubayashi H, Goggins M. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology 2006; 130: 548-565 [PMID: 16472607 DOI: 10.1053/j.gastro.2005.11.008]
80. Fukushima N, Walter KM, Uek T, Sato N, Matsubayashi H, Cameron JL, Hruban RH, Canto M, Yeo CJ, Goggins M. Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther 2003; 2: 78-83 [PMID: 12673124]
81. Matsubayashi H, Sato N, Fukushima N, Yeo CJ, Walter KM, Brune K, Sahin F, Hruban RH, Goggins M. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res 2003; 9: 1446-1452 [PMID: 12684418]
82. Fukushima N, Sato N, Sahin F, Su GH, Hruban RH, Goggins M. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer 2003; 89: 338-343 [PMID: 12865927 DOI: 10.1038/sj.bjc.6601039]
83. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, Hruban RH, Goggins M. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003; 22: 5021-5030 [PMID: 12902985 DOI: 10.1038/sj.onc.1206807]
84. Jansen M, Fukushima N, Rosty C, Walter K, Altink R, Heek TV, Hruban R, Offerhaus JG, Goggins M. Aberrant methylation of the 5′ CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther 2002; 1: 293-296 [PMID: 12432281]
85. Ueki T, Walter KM, Skinner H, Jaffee E, Hruban RH, Goggins M. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. Oncogene 2002; 21: 2114-2117 [PMID: 11960385 DOI: 10.1038/sj.onc.1205275]
86. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, Hruban RH, Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003; 63: 3735-3742 [PMID: 12839967]
87. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136: 187-195 [PMID: 18992248 DOI: 10.1053/j.gastro.2008.09.067]
88. Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012; 143: 664-74. e1-6 [PMID: 22705007 DOI: 10.1053/j.gastro.2012.06.006]
89. Johnston FM, Tan MC, Tan BR, Porembka MR, Brunt EM, Linehan DC, Simon PO, Plambeck-Suess S, Eberlein TJ, Hellstrom KE, Hellstrom I, Hawkins WG, Goedegebuure P. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 2009; 15: 6511-6518 [PMID: 19843662 DOI: 10.1158/1078-0432.CCR-09-0565]
90. Maitra A, Cohen Y, Gillespie SE, Mambo E, Fukushima N, Hoque MO, Shah N, Goggins M, Califano J, Sidransky D, Chakravarti A. The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res 2004; 14: 812-819 [PMID: 15123581 DOI: 10.1101/gr.2228504]
91. Zakharova OP, Karmazanovsky GG, Egorov VI. Pancreatic adenocarcinoma: Outstanding problems. World J Gastrointest Surg 2012; 4: 104-113 [PMID: 22655124 DOI: 10.4240/wjgs.v4.i5.104]
92. Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, Slater EP, Heverhagen JT, Gress TM, Rothmund M, Bartsch DK. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009; 58: 1410-1418 [PMID: 19470496 DOI: 10.1136/gut.2008.171611]
93. Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, van Eijck CH, Cats A, Kuipers EJ, Nio Y, Fockens P, Bruno MJ. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009; 104: 2175-2181 [PMID: 19491823 DOI: 10.1038/ajg.2009.276]
94. Vasen HF, Wasser M, van Mil A, Tollenaar RA, Konstantinovski M, Gruis NA, Bergman W, Hes FJ, Hommes DW, Offerhaus GJ, Morreau H, Bonsing BA, de Vos tot Nederveen Cappel WH. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 2011; 140: 850-856 [PMID: 21129377 DOI: 10.1053/j.gastro.2010.11.048]
95. Raut CP, Grau AM, Staerkel GA, Kaw M, Tamm EP, Wolff RA, Vauthey JN, Lee JE, Pisters PW, Evans DB. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 2003; 7: 118-26; discussion 127-8 [PMID: 12559193]
96. Gheonea DI, Sãftoiu A. Beyond conventional endoscopic ultrasound: elastography, contrast enhancement and hybrid techniques. Curr Opin Gastroenterol 2011; 27: 423-429 [PMID: 21844751 DOI: 10.1097/MOG.0b013e328349cfab]
97. Kitano M, Kudo M, Maekawa K, Suetomi Y, Sakamoto H, Fukuta N, Nakaoka R, Kawasaki T. Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography. Gut 2004; 53: 854-859 [PMID: 15138213 DOI: 10.1136/gut.2003.029934]
98. DeWitt J, Devereaux B, Chriswell M, McGreevy K, Howard T, Imperiale TF, Ciaccia D, Lane KA, Maglinte D, Kopecky K, LeBlanc J, McHenry L, Madura J, Aisen A, Cramer H, Cummings O, Sherman S. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 2004; 141: 753-763 [PMID: 15545675 DOI: 10.7326/0003-4819-141-10-200 411160-00006]
99. Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I, Coste J, Louvel A, Roseau G, Couturier D, Bonnin A. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol 1998; 170: 1315-1322 [PMID: 9574609 DOI: 10.2214/ajr.170.5.9574609]
100. Miller FH, Rini NJ, Keppke AL. MRI of adenocarcinoma of the pancreas. AJR Am J Roentgenol 2006; 187: W365-W374 [PMID: 16985107 DOI: 10.2214/AJR.05.0875]
101. Tadic M, Kujundzic M, Stoos-Veic T, Kaic G, Vukelic-Markovic M. Role of repeated endoscopic ultrasound-guided fine needle aspiration in small solid pancreatic masses with previous indeterminate and negative cytological findings. Dig Dis 2008; 26: 377-382 [PMID: 19188731 DOI: 10.1159/000177025]
102. Brennan DD, Zamboni GA, Raptopoulos VD, Kruskal JB. Comprehensive preoperative assessment of pancreatic adenocarcinoma with 64-section volumetric CT. Radiographics 2007; 27: 1653-1666 [PMID: 18025509 DOI: 10.1148/rg.276075034]
103. Bronstein YL, Loyer EM, Kaur H, Choi H, David C, DuBrow RA, Broemeling LD, Cleary KR, Charnsangavej C. Detection of small pancreatic tumors with multiphasic helical CT. AJR Am J Roentgenol 2004; 182: 619-623 [PMID: 14975959 DOI: 10.2214/ajr.182.3.1820619]
104. Diehl SJ, Lehmann KJ, Sadick M, Lachmann R, Georgi M. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998; 206: 373-378 [PMID: 9457188]
105. Agarwal B, Abu-Hamda E, Molke KL, Correa AM, Ho L. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol 2004; 99: 844-850 [PMID: 15128348 DOI: 10.1111/j.1572-0241.2004.04177.x]
106. Shimizu Y, Yasui K, Matsueda K, Yanagisawa A, Yamao K. Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and postoperative results from a single institute. J Gastroenterol Hepatol 2005; 20: 1591-1594 [PMID: 16174079 DOI: 10.1111/j.1440-1746.2005.03895.x]
107. Takeshita K, Furui S, Yamauchi T, Harasawa A, Kohtake H, Sasaki Y, Suzuki S, Tanaka H, Takeshita T. [Minimum intensity projection image and curved reformation image of the main pancreatic duct obtained by helical CT in patients with main pancreatic duct dilation]. Nihon Igaku Hoshasen Gakkai Zasshi 1999; 59: 146-148 [PMID: 10349314]
108. Nino-Murcia M, Jeffrey RB, Beaulieu CF, Li KC, Rubin GD. Multidetector CT of the pancreas and bile duct system: value of curved planar reformations. AJR Am J Roentgenol 2001; 176: 689-693 [PMID: 11222206 DOI: 10.2214/ajr.176.3.1760689]
109. Fusari M, Maurea S, Imbriaco M, Mollica C, Avitabile G, Soscia F, Camera L, Salvatore M. Comparison between multislice CT and MR imaging in the diagnostic evaluation of patients with pancreatic masses. Radiol Med 2010; 115: 453-466 [PMID: 20077047 DOI: 10.1007/s11547-010-0490-7]
110. Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg 2007; 70: 331-338 [PMID: 18330088]
111. Lee JK, Kim AY, Kim PN, Lee MG, Ha HK. Prediction of vascular involvement and resectability by multidetector-row CT versus MR imaging with MR angiography in patients who underwent surgery for resection of pancreatic ductal adenocarcinoma. Eur J Radiol 2010; 73: 310-316 [PMID: 19070981 DOI: 10.1016/j.ejrad.2008.10.028]
112. Park HS, Lee JM, Choi HK, Hong SH, Han JK, Choi BI. Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT. J Magn Reson Imaging 2009; 30: 586-595 [PMID: 19711405 DOI: 10.1002/jmri.21889]
113. Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT, Eikman EA, Malafa M. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 2008; 15: 2465-2471 [PMID: 18551347 DOI: 10.1245/s10434-008-9992-0]
114. Okano K, Kakinoki K, Akamoto S, Hagiike M, Usuki H, Yamamoto Y, Nishiyama Y, Suzuki Y. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol 2011; 17: 231-235 [PMID: 21245997 DOI: 10.3748/wjg.v17.i2.231]
115. Tang S, Huang G, Liu J, Liu T, Treven L, Song S, Zhang C, Pan L, Zhang T. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur J Radiol 2011; 78: 142-150 [PMID: 19854016 DOI: 10.1016/j.ejrad.2009.09.026]
116. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S-93S [PMID: 11483694]
117. Pakzad F, Groves AM, Ell PJ. The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 2006; 36: 248-256 [PMID: 16762614 DOI: 10.1053/j.semnuclmed.2006.03.005]